Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes: The TODAY experience

Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO). Obese 10- to 17-year...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2013-06, Vol.36 (6), p.1765-1771
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Biological and medical sciences Blood Glucose - drug effects Care and treatment Child Children & youth Clinical trials Committees Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes therapy Diabetes. Impaired glucose tolerance Disease Drug Combinations Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glycated Hemoglobin A - metabolism Heart attacks Heart failure Hemoglobin Humans Hypoglycemia Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Male Medical sciences Metabolic diseases Metformin - adverse effects Metformin - therapeutic use Miscellaneous Mortality Original Research Public health. Hygiene Public health. Hygiene-occupational medicine Teenagers Thiazoles - adverse effects Thiazoles - therapeutic use Type 2 diabetes Youth
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO). Obese 10- to 17-year-olds (N = 699) with type 2 diabetes for
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc12-2390